

Pharmacy Prior Approval Request for Immunomodulators: Actemra

Beneficiary Information			
1. Beneficiary Last Name:	2. First Name:		
	4. Beneficiary Date of Birth:5. Beneficiary Gender:		
Prescriber Information			
6. Prescribing Provider NPI #:			
	n - Name:		Ext
Drug Information			
8. Drug Name:	9. Strength:	10. Quantity P	er 30 Days:
11. Length of Therapy (in days):	☐ up to 30 Days ☐ 60 Days ☐ 9	0 Days □ 120 Days □	180 Days □ 365
Days Other			
Clinical Information			
3. Has the beneficiary been considered. Has the beneficiary been tested. Has the beneficiary tried one methotrexate, leflunomide or due to contraindications? 6. Does the beneficiary have PJIA. Has the beneficiary had a trial Enbrel or Humira? Yes No Request for Systemic Onset Juve 1. Does the beneficiary have a discontinuous disc	A subtype enthesitis related arthriti and failure of Enbrel or Humira or a	of latent tuberculosis info s	one) or ke these therapies iary cannot try
3. Has the beneficiary been consi4. Has the beneficiary been teste5. Does the beneficiary have sys	idered and screened for the presence of with Hep B SAG and Core Ab? Yes temic arthritis with active systemic ing physician (e.g. arthritis of the himself.)	of latent tuberculosis info □ No features and features	of poor prognosis,

Fax this form to (833) 404-2393



Pharmacy Prior Approval Request for Immunomodulators: Actemra

Request for Rheumatoid Arthritis:
1. Does the beneficiary have a diagnosis of Rheumatoid Arthritis? ☐ Yes ☐ No
2. Is the beneficiary not on another injectable biologic immunomodulator? \square Yes \square No
3. Has the beneficiary been considered and screened for the presence of latent tuberculosis infection? Yes No
4. Has the beneficiary been tested with Hep B SAG and Core Ab? ☐ Yes ☐ No
5. Has the beneficiary experienced a therapeutic failure/inadequate response with methotrexate or at least one disease modifying antirheumatic drug (e.g. leflunomide, hydroxychloroquine, minocycline sulfasalazine)? Yes No
6. Is the beneficiary unable to receive methotrexate or disease modifying antirheumatic drug due to contraindications or intolerabilities? ☐ Yes ☐ No
7. Does the beneficiary have clinical evidence of severe or rapidly progressing disease? ☐ Yes ☐ No
8. Has the beneficiary had a trial and failure of Enbrel or Humira or a clinical reason beneficiary cannot try either Enbrel or Humira? Yes No
Request for Giant Cell Arteritis:
1. Does the beneficiary have a diagnosis of Giant Cell Arteritis? Yes No
2. Is the beneficiary not on another injectable biologic immunomodulator? \square Yes \square No
3. Has the beneficiary been considered and screened for the presence of latent tuberculosis infection? Yes No
4. Has the beneficiary been tested with Hep B SAG and Core Ab \square Yes \square No
Request for Cytokine Release Syndrome:
1. Does the beneficiary have a diagnosis of Cytokine Release Syndrome? ☐ Yes ☐ No
2. Is the beneficiary not on another injectable biologic immunomodulator? \square Yes \square No
3. Has the beneficiary been considered and screened for the presence of latent tuberculosis infection? \square Yes \square No
4. Has the beneficiary been tested with Hep B SAG and Core Ab? \square Yes \square No
Request for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
1. Does the beneficiary have a diagnosis of Systemic Sclerosis-Associated Interstitial Lung Disease? \square Yes \square No
2. Is the beneficiary not on another injectable biologic immunomodulator? \square Yes \square No
3. Has the beneficiary been considered and screened for the presence of latent tuberculosis infection? \square Yes \square No
4. Has the beneficiary been tested with Hep B SAG and Core Ab? \square Yes \square No
Signature of Prescriber: Date:
(Prescriber Signature Mandatory)

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.

Fax this form to (833) 404-2393